Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2013

Habibollahi P, van den Berg NS, Kuruppu D, Loda M, Mahmood U. Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging. J Nucl Med. 2013;54(2):252-8.

Zhang Y, Shin SJ, Liu D, Ivanova E, Foerster F, Ying H, et al. ZNF365 promotes stability of fragile sites and telomeres. Cancer Discov. 2013;3(7):798-811.

Ohsawa R, Seol J-, Tyler JK. At the intersection of non-coding transcription, DNA repair, chromatin structure, and cellular senescence. Front Genet. 2013;4:136.

Fatima N, Cohen C, Lawson D, Siddiqui MT. Automated and manual human papilloma virus in situ hybridization and p16 immunohistochemistry: comparison in metastatic oropharyngeal carcinoma. Acta Cytol. 2013;57(6):633-40.

Mosquera JM, Sboner A, Zhang L, Kitabayashi N, Chen C-, Sung YS, et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer. 2013;52(6):538-50.

Liang SY, Westblade LF, Mehrtens J, Burnham C-, F Kuhlmann M. Fever in a 20-year-old returned traveler. Clin Infect Dis. 2013;56(3):423; answers 461-2.

Rychert J, Burnham C-, Bythrow M, Garner OB, Ginocchio CC, Jennemann R, et al. Multicenter evaluation of the Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry system for identification of Gram-positive aerobic bacteria. J Clin Microbiol. 2013;51(7):2225-31.

Bisig B, de Reyniès A, Bonnet C, Sujobert P, Rickman DS, Marafioti T, et al. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica. 2013;98(8):1250-8.

Clozel T, Yang SN, Elstrom RL, Tam W, Martin P, Kormaksson M, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 2013;3(9):1002-19.

Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134-40.